Capricor Therapeutics (CAPR) AI Stock Analysis

• Market Cap: $287.10M
• Dividend Yield: N/A
• Average Volume (3M): 1.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.47
• Revenue Growth: -50.68%
• EPS Growth: -76.38%
• Country: US
• Employees: 160
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.57
• Shares Outstanding: 45,716,976
• 10 Day Avg. Volume: 1,509,491
• 30 Day Avg. Volume: 1,272,608
• PEG Ratio: -0.31
• Price to Book (P/B): 3.34
• Price to Sales (P/S): 21.82
• P/FCF Ratio: -11.70
• Enterprise Value/Market Cap: 1.17
• Enterprise Value/Revenue: 25.05
• Enterprise Value/Gross Profit: 28.52
• Enterprise Value/Ebitda: -4.79
• 1Y Price Target: $22.17
• Price Target Upside: 273.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 6
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 46 Neutral
• Price Target: $6.00 ▲(1.18% Upside)

Capricor Therapeutics' overall stock score is primarily impacted by its financial struggles, including negative profitability and cash flow issues, compounded by regulatory setbacks and zero revenue. While the company maintains a strong cash position, the bearish technical indicators and negative valuation metrics further weigh down the score.

Positive Factors

Strong Cash Position

A robust cash position ensures Capricor can sustain operations and fund R&D efforts, providing stability and strategic flexibility.

Progress in Exosome Program

Advancements in the exosome program highlight Capricor's innovative capabilities, potentially leading to new revenue streams and partnerships.

Manufacturing and CMC Readiness

FDA validation of manufacturing processes enhances Capricor's credibility and readiness for product commercialization, supporting long-term growth.

Negative Factors

Complete Response Letter from FDA

The FDA's CRL creates regulatory hurdles, delaying product approval and impacting Capricor's ability to generate revenue from Deramiocel.

Increased Operating Expenses

Rising R&D expenses strain financial resources, potentially impacting profitability and necessitating efficient cost management to sustain operations.

Zero Revenue Reported

Zero revenue highlights challenges in product commercialization, affecting financial stability and necessitating successful product launches to improve outlook.

Capricor Therapeutics Business Overview & Revenue Model

Company Description

Capricor Therapeutics (CAPR) is a biotechnology company focused on developing innovative therapies for the treatment of rare cardiovascular diseases and disorders. The company specializes in regenerative medicine, particularly using its proprietary exosome platform technology derived from cardiac stem cells. Capricor's core products include CAP-1002, an investigational drug aimed at treating Duchenne muscular dystrophy and other related conditions, as well as additional therapeutic candidates targeting various indications in the cardiovascular space.

How the Company Makes Money

Capricor Therapeutics generates revenue primarily through the development and commercialization of its therapeutic products. The company may engage in various revenue streams, including licensing agreements, collaborations with pharmaceutical companies, and government grants for research and development. Significant partnerships with larger biotech or pharmaceutical firms may provide upfront payments, milestone payments, and royalties on future sales, contributing to Capricor's earnings. Additionally, funding from grants or public offerings may support its operational costs and research initiatives.

Capricor Therapeutics Financial Statement Overview

Summary

Capricor Therapeutics faces significant financial challenges typical of the biotechnology sector, with negative profitability and cash flow issues despite a strong equity position. Revenue growth is present but overshadowed by operational inefficiencies and persistent losses.

Income Statement

Capricor Therapeutics has shown significant revenue volatility over the years, with a notable increase in revenue in 2023 compared to previous years, but still operates at a net loss. The gross profit margin is consistently negative, and the EBIT and EBITDA margins are also negative, indicating the company is struggling with profitability. Revenue growth is present but overshadowed by operational inefficiencies and high expenses.

Balance Sheet

The company has a strong equity position with a positive stockholders' equity, and the absence of total debt in the latest year indicates reduced leverage risk. However, the negative total liabilities figure in 2024 raises concerns about data accuracy or financial reporting issues. The equity ratio is favorable given the high equity levels in relation to assets.

Cash Flow

Capricor Therapeutics has experienced fluctuating cash flow from operations, with periods of negative free cash flow, indicating challenges in generating sustainable cash from operations. The free cash flow growth rate is negative, and the operating cash flow to net income ratio is not calculable, highlighting ongoing cash management issues.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	13.39M	22.27M	25.18M	2.55M	244.90K	310.25K
Gross Profit	11.76M	20.84M	24.11M	1.86M	-798.00	310.25K
EBITDA	-69.99M	-41.14M	-23.01M	-29.16M	-20.69M	-13.55M
Net Income	-69.98M	-40.47M	-22.29M	-29.02M	-20.02M	-13.66M
Balance Sheet
Total Assets	133.57M	170.48M	58.73M	50.09M	41.33M	34.62M
Cash, Cash Equivalents and Short-Term Investments	122.80M	151.52M	39.49M	41.42M	34.89M	32.67M
Total Debt	1.04M	1.45M	2.24M	2.56M	2.87M	318.16K
Total Liabilities	28.59M	25.02M	36.13M	38.31M	9.96M	6.42M
Stockholders Equity	104.98M	145.46M	22.60M	11.79M	31.37M	28.20M
Cash Flow
Free Cash Flow	-56.38M	-41.53M	-27.64M	1.56M	-18.01M	-10.60M
Operating Cash Flow	-52.99M	-40.00M	-25.60M	4.92M	-16.81M	-10.05M
Investing Cash Flow	-82.94M	-116.18M	5.11M	-35.07M	-1.20M	5.44M
Financing Cash Flow	148.48M	152.77M	25.58M	4.87M	20.23M	33.38M

Capricor Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CAPR, the sentiment is Negative. The current price of 5.93 is below the 20-day moving average (MA) of 6.32, below the 50-day MA of 6.57, and below the 200-day MA of 9.75, indicating a bearish trend. The MACD of -0.19 indicates Positive momentum. The RSI at 41.78 is Neutral, neither overbought nor oversold. The STOCH value of 16.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CAPR.

Capricor Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FDMT	58 Neutral	$509.99M	―	-38.87%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CAPR	46 Neutral	$287.10M	―	-120.15%	―	-50.68%	-76.38%
ALEC	45 Neutral	$131.58M	―	-121.98%	―	12.26%	37.36%
IMAB	45 Neutral	―	―	―	―	-100.00%	72.45%
HUMA	42 Neutral	$249.07M	―	―	―	―	63.92%
GALT	35 Underperform	$363.22M	-8.81	―	―	―	17.80%

Capricor Therapeutics Corporate Events

Capricor Therapeutics Faces Challenges Despite Strong Cash Position

Capricor Therapeutics’ recent earnings call presented a mixed sentiment, highlighting both strengths and challenges. The company showcased its robust cash position and progress in its exosome program, yet faced hurdles with the FDA’s complete response letter, rising expenses, and zero revenue, culminating in a net loss. Regulatory delays and uncertainty surrounding Deramiocel’s approval path further contributed to a negative outlook.

Capricor Therapeutics: Q2 2025 Financial and Strategic Update

Capricor Therapeutics, Inc. is a biotechnology company focused on developing innovative cell and exosome-based therapies for rare diseases, with a leading candidate aimed at treating Duchenne Muscular Dystrophy (DMD).